Results 161 to 170 of about 344,235 (297)

HLA class-I-transgenic mice as model system to study MHC-restricted antigen recognition in man [PDF]

, 1990
A. McMichael, C. Botteron, Chamberlain J-W, Dill O, E. H. Weiss, Engelhard V H, F. Kievits, G. Brem, G. Riethmüller, G. Schliesser, Kievits F, Kievits K, Krimpenfort P, Le A-T, P. Ivanyi, Pohla H, Taurog J D, Thurau S R, Weiss E H, Weiss E H   +19 more
core   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

Immune cells in keloids: mechanisms and potential treatments. [PDF]

Ann Med
Wu Y, Huang Y, Zhang H, Dong C, Chen X.
europepmc   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

Advanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun, Qihong Li, Bixi Wang, Gang Wang, Ying Xue, Yibing Liang, Chenhe Hu, Zhenyu Wang, Xiaoge Gao, Haiheng Xu, Jun Song, Hailong Li, Liantao Li, Xiaoxiao Liu, Patrick Ming‐Kuen Tang, Qing Zhang   +15 more
wiley   +1 more source

Beyond the Th2 paradigm: CD4+ cytotoxic T lymphocytes as key drivers of tissue damage and fibrosis in IgG4-related disease. [PDF]

Front Immunol
Yi J, Jia L, Mao T, Li Z.
europepmc   +1 more source

Identification of murine H-2Db histocompatibility antigens in cells transfected with cloned H-2 genes [PDF]

, 1985
Ferluga, J., Festenstein, H., Schmidt, Walter, Weiss, Elisabeth H.   +3 more
core   +1 more source

A Mitochondria‐Specific Nanomedicine for Synergistic Chemo‐Photothermal Therapy and Immunogenic Activation Against Breast Cancer

Advanced Science, EarlyView.
Peptide dendrimer–based nanoplatform with mitochondria‐targeting capability was developed for synergistic chemo‐photothermal therapy. The system promotes efficient transcytosis, induces mitochondrial dysfunction, triggers immunogenic cell death (ICD), and enhance antitumor immunity by promoting dendritic cell maturation and T‐cell activation, resulting
Min Li, Jiangqi Feng, Junyang Zhuang, Qingguo Zhong, Yanda Li, Yanzhuo Lv, Shaoteng Huang, Xiangyu Huang, Mingbo Zhang, Xiaofeng Cai, Yuxin Wang, Wenping Chen, Zhenyu Duan, Zhou Chen, Kui Luo, Ning Li   +15 more
wiley   +1 more source

Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma-A Systematic Review. [PDF]

Dermatopathology (Basel)
Loo LY, Tay SH, Oh CC.
europepmc   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

Innate and adaptive immune patterns in hospitalised COVID-19 patients: a framework for precision monitoring in viral and inflammatory syndromes. [PDF]

Front Immunol
Corrao S, Bocchio RM, Scibetta S, Montalbano A, Natoli G, Calvo L, Gervasi F, Argano C, Internal Medicine IGR COVID-19 Investigators.   +8 more
europepmc   +1 more source